Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida.
2024年6月6日，賓夕法尼亞州韋恩市（GLOBE NEWSWIRE） - Aclaris Therapeutics，Inc.（納斯達克：ACRS）是一家臨床階段的生物製藥公司，專注於開發針對免疫炎症性疾病的新型藥物候選品。今天宣佈，Aclaris的代總裁兼首席執行官Neal Walker博士將於2024年6月11日星期二美國佛羅里達州邁阿密時間上午11:20參加高盛第45屆全球醫療保健會議期間的座談會。
A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
可以通過Aclaris網站“投資者”部分的“事件”頁面訪問座談會的網絡直播。www.aclaristx.comAclaris Therapeutics, Inc.是一家臨床階段的生物製藥公司，開發的新型藥物候選物能夠應對免疫炎症性疾病患者在缺乏滿意治療方法的情況下的需求。公司擁有一個多階段的藥物候選物組合，由一個探索蛋白激酶調節的強大的研發引擎提供支持。詳情請訪問其網站。
About Aclaris Therapeutics, Inc.
關於Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics, Inc.是一家臨床階段的生物製藥公司，開發的新型藥物候選物能夠應對免疫炎症性疾病患者在缺乏滿意治療方法的情況下的需求。公司擁有一個多階段的藥物候選物組合，由一個探索蛋白激酶調節的強大的研發引擎提供支持。詳情請訪問其網站。www.aclaristx.com.
Aclaris Therapeutics Contact:
Aclaris Therapeutics 聯繫方式：
Source: Aclaris Therapeutics, Inc.
來源：aclairs therapeutics, Inc.
譯文內容由第三人軟體翻譯。